about
Acetylcholinesterase inhibitor treatment for myasthenia gravisThymectomy for non-thymomatous myasthenia gravisMedical and surgical treatment for ocular myastheniaAcetylcholinesterase inhibitor treatment for myasthenia gravisThymectomy for non-thymomatous myasthenia gravisImmunosuppressive agents for myasthenia gravisMedical and surgical treatment for ocular myastheniaMedical and surgical treatment for ocular myastheniaPleiotropic effects of the 8.1 HLA haplotype in patients with autoimmune myasthenia gravis and thymus hyperplasiaCathepsin V is involved in the degradation of invariant chain in human thymus and is overexpressed in myasthenia gravisMyasthenia gravis and thymic neoplasms: A brief reviewMapping autoantigen epitopes: molecular insights into autoantibody-associated disorders of the nervous systemRole of regulatory b cells in neuroimmunologic disordersExtracorporeal whole blood immunoadsorption of autoimmune myasthenia gravis by cellulose tryptophan adsorbentFunctional and Biochemical Characterization of Alvinella pompejana Cys-Loop Receptor HomologuesRisk for myasthenia gravis maps to a (151) Pro→Ala change in TNIP1 and to human leukocyte antigen-B*08An adult patient with new-onset dysphagiaIdentification of novel MicroRNA signatures linked to experimental autoimmune myasthenia gravis pathogenesis: down-regulated miR-145 promotes pathogenetic Th17 cell response.Carbonic anhydrase III is insufficient in muscles of myasthenia gravis patients.Structural insights into the molecular mechanisms of myasthenia gravis and their therapeutic implications.Improved methodology to obtain large quantities of correctly folded recombinant N-terminal extracellular domain of the human muscle acetylcholine receptor for inducing experimental autoimmune myasthenia gravis in rats.Specific immunotherapy of experimental myasthenia gravis by a novel mechanism.Correlation of anti-signal recognition particle autoantibody levels with creatine kinase activity in patients with necrotizing myopathy.Autoantibodies to agrin in myasthenia gravis patients.Perioperative management in myasthenia gravis: republication of a systematic review and a proposal by the guideline committee of the Japanese Association for Chest Surgery 2014.In vivo adsorption of autoantibodies in myasthenia gravis using Nanodisc-incorporated acetylcholine receptor.Quality of life and life circumstances in German myasthenia gravis patients.Alternatively spliced transcripts of the thymus-specific protease PRSS16 are differentially expressed in human thymus.Comparison of IVIg and PLEX in patients with myasthenia gravis.Plasma exchange for myasthenia gravis.Analysis of serum miRNA profiles of myasthenia gravis patients.Circulating regulatory anti-T cell receptor antibodies in patients with myasthenia gravis.Disorders of the respiratory muscles.Effect of complement and its regulation on myasthenia gravis pathogenesis.Anaesthetic considerations in paediatric myasthenia gravis.Direct proof of the in vivo pathogenic role of the AChR autoantibodies from myasthenia gravis patientsEvidence of underdiagnosis of myasthenia gravis in older people.Differential Cytokine Changes in Patients with Myasthenia Gravis with Antibodies against AChR and MuSK.Myasthenia Gravis during the Course of Neuromyelitis Optica.Myasthenogenicity of the main immunogenic region and endogenous muscle nicotinic acetylcholine receptors
P2860
Q24193114-708103F3-FC13-45A8-A972-B6176AA6EF56Q24197482-2485F5C2-2AE2-4001-AC29-A1C58882BD16Q24202289-70562F1A-32C5-45D6-897A-A993D6E87E58Q24234121-77CA150F-C512-4A41-9E2C-82E1964DD959Q24240863-795EB9A9-E562-4500-AEF6-67C603F91E86Q24243208-8D14D05B-E0A2-43FA-BB28-8213856E9B20Q24245255-73ADB7B5-995A-445C-9BD4-41E42BC11581Q24246392-9182CCA5-6806-4980-8C63-B90E0D48E198Q24562160-1CDF7A43-F3AD-4379-83F2-EC3E30170DE8Q24679698-1148E9B4-D4C9-4E10-8F8B-AE34B99EFDFAQ26775077-A2CE72B5-ED70-4E2A-808D-F7E248AE2A8CQ28075974-F7D4F2F0-A014-4772-8071-A60DD1C647C5Q28077219-CFAB4971-7E58-446A-9A19-DF7E12333E9FQ28258023-0706FC8C-CA6D-4A8F-BB6A-BD83CE21774AQ28550915-7AB81E34-3D11-40EC-8AED-835877D74D9CQ28943379-021C6A91-9882-48A4-803A-1473D2ECFE02Q30478205-38C39D04-9F4B-462A-B8F7-E7CCC188472EQ30667392-9AA6B6AB-CE8D-459E-8343-DE78D8DCEC33Q33419952-F818247F-D3DF-411C-BBF2-C7B7A85E1F4CQ33602986-698B795D-7245-4E2F-B52A-337B54E3E55CQ33701244-2136A525-7A19-4475-8AF0-DD87F15D46C7Q33831279-451818C5-E556-4FB9-88FF-A8AD3A7A89B5Q33844947-2B3D6E9E-B173-4C97-9C65-399FC9910D98Q34040180-FECA6804-0B57-4877-8124-879C9DED34F2Q34043022-143DD1F5-818A-49FF-8303-FAF6D39DC91AQ34127035-7AE4D523-2BD8-4B44-B08E-1477DCA34F4CQ34366471-CDC363F0-5C40-4873-901B-3E3DF76D9DF9Q34375581-B7713073-1C0F-497E-956B-2C3775525DFFQ35030406-F5928A56-297D-420D-B46D-25465E040388Q35041815-A3250E6B-0F10-47D8-B5F2-6EA67DC13144Q35122838-8B7D955A-0C0B-402C-80C5-34E6A2B6863FQ35140380-0C7F5472-5BA4-4733-9349-8792EDDAD199Q35162640-AC9DDC91-041E-404F-A8E4-08E0DFE015B6Q35221722-9BC3DB2F-9CFA-4EEF-BBAF-4FFA74399B3BQ35231790-38575642-78D7-4B00-A9F7-09863D7166DBQ35279680-A71C96CB-0624-4EBF-8A4D-1CCBFF34FD3BQ35475427-7A03066D-BFCF-417C-BAB0-18E11ACB61E5Q35495592-6FF836F1-1714-4300-ABF9-6975FA7E9F5DQ35574206-44D26275-BD91-49D2-96B7-99D2780EDF40Q35649128-A85ABC8D-D80B-465A-AABB-32AEC4095166
P2860
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Myasthenia gravis
@ast
Myasthenia gravis
@en
type
label
Myasthenia gravis
@ast
Myasthenia gravis
@en
prefLabel
Myasthenia gravis
@ast
Myasthenia gravis
@en
P3181
P1433
P1476
Myasthenia gravis
@en
P2093
David Hilton-Jones
Jackie Palace
P304
P3181
P356
10.1016/S0140-6736(00)05186-2
P407
P577
2001-06-01T00:00:00Z